Ken Griffin Cyma Bay Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2023 Feb 14, 2024	SELL	$12.63 - $24.47 $1.31 Million - $2.53 Million	-103,500 Reduced 59.48%	70,500 $1.67 Million
Q3 2023 Nov 14, 2023	BUY	$10.86 - $17.62 $1.84 Million - $2.98 Million	169,400 Added 3682.61%	174,000 $2.59 Million
Q2 2023 Aug 14, 2023	SELL	$7.47 - $10.95 $126,990 - $186,150	-17,000 Reduced 78.7%	4,600 $50,000
Q1 2023 May 15, 2023	BUY	$5.88 - $9.59 $27,636 - $45,073	4,700 Added 27.81%	21,600 $188,000
Q4 2022 Feb 14, 2023	BUY	$3.22 - $6.27 $19,964 - $38,874	6,200 Added 57.94%	16,900 $105,000
Q3 2022 Nov 14, 2022	SELL	$2.77 - $4.25 $277 - $425	-100 Reduced 0.93%	10,700 $37,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.